SCHEMBL23923631

SCHEMBL23923631

N#Cc1c(N2CCN(C(=O)O)CC2)cc(F)c2c1OC[C@H](N)C2

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.33
MAPK1 P28482 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CHRM4 P08173 1/20 0.31
KDM1A O60341 4/20 0.31
SLC6A9 P48067 1/20 0.31
SLC6A5 Q9Y345 1/20 0.31
USP30 Q70CQ3 1/20 0.31
LMNA P02545 1/20 0.30
GRM5 P41594 1/20 0.30
KDM4E B2RXH2 2/20 0.30
ALOX15 P16050 1/20 0.30
AOC3 Q16853 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923634 1.00 DPP4 (0.33) DPP4MAPK1MEN1KMT2ACHRM4
SCHEMBL21704066 0.86 GPR119 (0.40) DPP4KDM4E
SCHEMBL21686014 0.84 MAPK1 (0.34) MAPK1MEN1KMT2ASLC6A5GRM5
SCHEMBL21686015 0.84 MAPK1 (0.34) MAPK1MEN1KMT2ASLC6A5GRM5
SCHEMBL20722741 0.84 MAPK1 (0.34) MAPK1MEN1KMT2ASLC6A5GRM5
SCHEMBL20731201 0.83 ALDH1A1 (0.44) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL20722948 0.83 MAPK1 (0.34) DPP4MAPK1CHRM4KDM1ALMNA
SCHEMBL20722664 0.83 MAPK1 (0.34) DPP4MAPK1CHRM4KDM1ALMNA
SCHEMBL21685898 0.83 MAPK1 (0.34) DPP4MAPK1CHRM4KDM1ALMNA
SCHEMBL21704087 0.78 USP28 (0.31) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 DPP4 378/4885MAPK1 2061/4885MEN1 3554/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 DPP4 378/4885MAPK1 2061/4885MEN1 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.